Original Research
Published on 16 Sep 2021
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2021.723966
- 4,907 views
- 4 citations
45 articles related to "Axitinib"
Articles
Original Research
Published on 08 May 2020
A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2020.00619
- 8,397 views
- 22 citations
Original Research
Published on 10 Nov 2023
Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway
in Translational Medicine
Frontiers in Medicine
doi 10.3389/fmed.2023.1256156
- 3,850 views
- 5 citations
Review
Published on 31 May 2023
The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1163967
- 7,542 views
- 24 citations
Case Report
Published on 26 Oct 2021
Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2021.728750
- 5,854 views
- 8 citations
Original Research
Published on 17 Jun 2024
Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1415846
- 4,695 views
- 9 citations
Original Research
Published on 15 Feb 2023
Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2023.1071816
- 2,166 views
- 3 citations
Original Research
Published on 22 Aug 2017
Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2017.00182
- 5,518 views
- 24 citations
Case Report
Published on 19 May 2025
Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1495446
- 2,386 views
- 2 citations
Original Research
Published on 19 May 2022
Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.861189
- 5,273 views
- 16 citations
Case Report
Published on 07 Dec 2021
Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.782166
- 2,947 views
- 8 citations
Original Research
Published on 19 Feb 2020
Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.00174
- 4,349 views
- 5 citations
Original Research
Published on 31 Jul 2023
Influence of two anti-tumor drugs, pazopanib, and axitinib, on the development and thyroid-axis of zebrafish (Danio rerio) embryos/larvae
in Thyroid Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1204678
- 3,716 views
- 5 citations
Case Report
Published on 11 Aug 2025
Significant response to toripalimab plus axitinib for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report and literature review
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1606414
- 2,219 views
Original Research
Published on 27 May 2025
Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1618898
- 2,105 views
Original Research
Published on 28 Sep 2016
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2016.00331
- 7,631 views
- 16 citations